Skip to main content

Weaver Lab

Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core

AUTHORS

Nance KDKellie D , Days ELEmily L , Weaver CDC David , Coldren AAnastasia , Farmer TDTiffany D , Cho HPHyekyung P , Niswender CMColleen M , Blobaum ALAnna L , Niswender KDKevin D , Lindsley CWCraig W . Journal of medicinal chemistry. 2017 02 03; 60(4). 1611-1616

ABSTRACT

A duplexed, functional multiaddition high throughput screen and subsequent optimization effort identified the first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive antagonist. Antagonist 5d not only blocked exendin-4-stimulated insulin release in islets but also lowered insulin levels while increasing blood glucose in vivo.